US2081934A - Cinnamic preparations for therapeutic uses - Google Patents

Cinnamic preparations for therapeutic uses Download PDF

Info

Publication number
US2081934A
US2081934A US51270A US5127035A US2081934A US 2081934 A US2081934 A US 2081934A US 51270 A US51270 A US 51270A US 5127035 A US5127035 A US 5127035A US 2081934 A US2081934 A US 2081934A
Authority
US
United States
Prior art keywords
cinnamic
ester
benzyl
preparations
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US51270A
Inventor
Jacobson Jacob
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US51270A priority Critical patent/US2081934A/en
Application granted granted Critical
Publication of US2081934A publication Critical patent/US2081934A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Definitions

  • the invention relates to therapeutic, preparations adapted for intramuscular or subcutaneous injections and containing benzyl cinnamic ester.
  • the object of the invention is to effect improvethe use of this the action of the benzyl ester of cinnamic acid has beneficial effects in connection with the treatment of a variety of diseased conditions of the humanbody has been siderable investigation and study and many publications bearing on the, subject are extant. Among such publications may be mentioned the following:
  • benzyl cinnamic ester 5 benzyl alcohol and cinnamicacid,althoughmean- 10 not derived from the cinnamic ester, and cinnamic acid resulting from the presence in the composition of the ethyl cinnamic ester.
  • Dosages of the preparation are then filled in ampules and sterilized.
  • the ordinary dosefor a normal patient is 1 cc., while for a less healthy patient a dose of V2 cc. is ordinarily used.
  • the dose for children is ordinarily /4 cc.
  • the preferred administration of the product is by way of intramuscular or subcutaneous-injection.
  • the efl'ect is in itself particularly" with respect to micro-orsanisms such as those of tetanus and diphtheria, though the preparationvis not to be regarded as a speciijlc for these organisms.
  • the fields of use and the type of diseased with which their use geous is that which is tions hereinabove referred to.
  • the method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamlc ester in henzyl alcohol in the general relation of 20 grams of the former-in about 15cc. of the latter and then incorporating the said solution with olive oil in the approximate proportion of 3.2 of the solution in 100 parts of the product, introducing dosages of the product into. ampules and sterilizing.
  • the method or preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic ester in benzyl alcohol in a general relation of 20 grams of the former in about 15 cc. of the latter, adding a cinnamic ester each gram of the benz yl other than the benzyl to said solution in the approximate proportion of of 1 cc. of said ester per gramot the benzyl cinnamic ester, introduclng dosages of the sterilizing.
  • the method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic, ester in benzyl alcohol product into ampules and in a general relation of 20 grams'oi the former in of the latter, adding ethyl cinnamic. solution in the approidmate propor- JAGOE JACOBSON.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

-Patented June 1, 1937 v zios sai PEUTIC USES 'CINNAMIO PREPARATIONS FOB f iacobJacobsom-Paris, France NoDrawing ggplication November 23, 1935,
rial No. 5
I 5 Claims. The invention relates to therapeutic, preparations adapted for intramuscular or subcutaneous injections and containing benzyl cinnamic ester. The object of the invention is to effect improvethe use of this the action of the benzyl ester of cinnamic acid has beneficial effects in connection with the treatment of a variety of diseased conditions of the humanbody has been siderable investigation and study and many publications bearing on the, subject are extant. Among such publications may be mentioned the following:
Comptes Rendue Soc. de Dermatologie of I February 9, 1922.-'Articles by Darier and Jean-.
selme and Jacobson;
Bulletin et Mm. de la Soc. md. des HQpJ, Reports of the Sessions of October 23, 1925, March 25, 1927, and April 19, 19 29; La Presse Mdicale, of March 13,
a by Gosset, Gutmann and Iahel; Paris Mdical, of qctober 25, 1930.--Article by 2 LVy-Solal, et a1.
Publication by Socit dOphtalmologie de Paris of February 1931; Articleby Chevallereau 8: 88891; La Tunisie Mdicale, April, 1932.--Report of the Commission de Tunisie. i a 30 Revenue Internationale du Trachomes, of January, 1932, and April, 1933, by Jean-Sedan. l
Archives de Mdecine et de Pharmacie Mili-q taires of February, 1933.-Article "by Barrel (8:
sm-mine Luc. rtevu r ntemationaie du Traohome of April,
1933- cle by Junes.
Bulletin of the'A cademy of Medicine.'-Report of the Session of July 18, 1933, Volume 110, No. 28 40 on Regression des kratites, etc." I According to published information on the-subject, the preparation employed is ordinarily. a solution or what is known in French as "ether benzyl cinnamique in olive oil in the proportion of 3.2 parts in one volume. In the French 45 hundred parts by a modern English chemical terminology word ether" in the combination represented by the- English word ester. The benzylic ester of cinnamic acid is, however, a. substance which is very difllcuitly soluble in olive oil.
50 I found that better results are obtainableif the percentage of 3.2 of the benzylic ester of cinnamic acid is reduced and in part replaced, within the approximate totality of 3.2 parts, by other ingredients, provided such other ments in products of the stated character with. reference to the physiological effects produced bytype of material. The fact that made the subject of constated would be ingredients are of such character as to contribute one or both of benzyl alcohol and cinnamic acid radicals. For example, if in-the non-oil parts ofthe product there are present in the following relation the following substances, (about 20 grams) benzyl alcohol (about 10-15 cc.) and ethyl cinnamic ester (about 2 co.) the 1111511 mate effect in the human body will apparently be a decomposition of the benzyl cinnamic ester into the,
to wit. benzyl cinnamic ester 5 benzyl alcohol and cinnamicacid,althoughmean- 10 not derived from the cinnamic ester, and cinnamic acid resulting from the presence in the composition of the ethyl cinnamic ester. position alsogre'atly facilitate the-production of a suspension or solution in olive oil inasmuch as a properly prepared solution of the benzyl cinnamic ester in benzyl alcohol, under avoidance of The components of the new com- 15 fusion of the benzyl cinnamic ester in an environ- 20 ment other than benzyl alcohol with the addition of the ethyl cinnamic ester, all in the approximate proportions stated, can be readily incorporated in pure refined olive oil. In the oil suspension the stated mixture of non-oil components preferably constitute about 3.2 parts in one hundred.
Dosages of the preparation are then filled in ampules and sterilized. The ordinary dosefor a normal patient is 1 cc., while for a less healthy patient a dose of V2 cc. is ordinarily used. The dose for children is ordinarily /4 cc. The preferred administration of the product is by way of intramuscular or subcutaneous-injection. The efl'ect is in itself particularly" with respect to micro-orsanisms such as those of tetanus and diphtheria, though the preparationvis not to be regarded as a speciijlc for these organisms. The fields of use and the type of diseased with which their use geous is that which is tions hereinabove referred to.
I claim:
1. A sterilized preparatiorf'constituted of an olive oil suspension of a mixture containing benzyl cinnamic ester and benzyl alcoholin the approximate relation of 20 grams of the former in 15 cc. of the latter and with a total of suspended material approxiis particularly advantain claim 1 in which the non-oily componen -elude ethyl cinnamic indicated by the publicaharmless and even anti-toxic,
conditions in connection ampule-contained therapeutic lation of of 1 cc. for cinnamic ester.
3. The method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamlc ester in henzyl alcohol in the general relation of 20 grams of the former-in about 15cc. of the latter and then incorporating the said solution with olive oil in the approximate proportion of 3.2 of the solution in 100 parts of the product, introducing dosages of the product into. ampules and sterilizing.
4. The method or preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic ester in benzyl alcohol in a general relation of 20 grams of the former in about 15 cc. of the latter, adding a cinnamic ester each gram of the benz yl other than the benzyl to said solution in the approximate proportion of of 1 cc. of said ester per gramot the benzyl cinnamic ester, introduclng dosages of the sterilizing.
5. The method of preparing a therapeutic preparation which comprises establishing a solution of benzyl cinnamic, ester in benzyl alcohol product into ampules and in a general relation of 20 grams'oi the former in of the latter, adding ethyl cinnamic. solution in the approidmate propor- JAGOE JACOBSON.
US51270A 1935-11-23 1935-11-23 Cinnamic preparations for therapeutic uses Expired - Lifetime US2081934A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US51270A US2081934A (en) 1935-11-23 1935-11-23 Cinnamic preparations for therapeutic uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51270A US2081934A (en) 1935-11-23 1935-11-23 Cinnamic preparations for therapeutic uses

Publications (1)

Publication Number Publication Date
US2081934A true US2081934A (en) 1937-06-01

Family

ID=21970269

Family Applications (1)

Application Number Title Priority Date Filing Date
US51270A Expired - Lifetime US2081934A (en) 1935-11-23 1935-11-23 Cinnamic preparations for therapeutic uses

Country Status (1)

Country Link
US (1) US2081934A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2592149A (en) * 1949-04-09 1952-04-08 Jacobson Jacob Therapeutic preparation comprising benzyl cinnamate and vitamin a
US2675342A (en) * 1950-09-30 1954-04-13 Schering Corp Supersaturated oil solutions of steroid hormones
US3105793A (en) * 1956-11-28 1963-10-01 Lobel Mervyn Joseph Injectable medicinal composition

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2592149A (en) * 1949-04-09 1952-04-08 Jacobson Jacob Therapeutic preparation comprising benzyl cinnamate and vitamin a
US2675342A (en) * 1950-09-30 1954-04-13 Schering Corp Supersaturated oil solutions of steroid hormones
US3105793A (en) * 1956-11-28 1963-10-01 Lobel Mervyn Joseph Injectable medicinal composition

Similar Documents

Publication Publication Date Title
DE2513797C2 (en) PHARMACEUTICAL COMPOSITION
US4798846A (en) Pharmaceutical compositions
CH693764A5 (en) A pharmaceutical composition comprising propofol and edetate.
US3070499A (en) Parenteral aqueous solutions of fat soluble vitamins
JP2000273061A (en) Terpenoid emulsion
EP0163924B1 (en) Vitamin medicine for the treatment and protection of mucous membranes, and use of vitamin e for manufacturing the medicine
US2081934A (en) Cinnamic preparations for therapeutic uses
JPH05501542A (en) Use of C-20 to C-26 fatty alcohols in the treatment of viral infections
Modell Drugs in Current Use 1958
DE2262427A1 (en) IMMUNOSTIMULATING AGENT AND METHOD FOR PREPARING IT
EP0238198A2 (en) Method of modifying the lipid structure function and expression of cell membranes and pharmaceutical compositions for use therein
US2744851A (en) Cardiac glycosides for intramuscular injection
US3894153A (en) Method of medical treatment of asthma
US2916417A (en) Article of manufacture
US3885030A (en) Medicine comprising lysine by-products
US3781422A (en) Therapeutic solution of iron and liposoluble vitamins
Winter et al. Effect of steroids upon resistance of skin to intracutaneous injection
US3032468A (en) Method particularly suitable for the prevention of paresis puerperalis in cattle
Mostert et al. Observations on the haemolytic activity of guaiacol glycerol ether
EP3328356A1 (en) Concentrate containing alprostadil
US2592149A (en) Therapeutic preparation comprising benzyl cinnamate and vitamin a
Friedlander et al. Studies in thrombo-angiitis obliterans (Buerger) X. Reduction in blood volume following bilateral oophorectomy
Crankshaw et al. The short term distribution of thiopentone in the dog
CN112315901A (en) Concentrated solution for injection and preparation method thereof
Shonle The Chemical Basis of Hypnotic Action as an Index of Clinical Efficiency.